Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**HQZ60** is an oral traditional Chinese medicine detoxification and rash reduction granule formulation being clinically studied for management of epidermal growth factor receptor tyrosine kinase inhibitor related skin rash in adults with epidermal growth factor receptor mutation positive non-small cell lung cancer. Its individual active constituents, molecular targets, and defined pharmacologic mechanism have not been publicly disclosed; therefore, it is best characterized as an investigational herbal medicine formulation intended for supportive treatment of EGFR-TKI-associated drug eruption. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=234631))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HQZ60.